We are live on
!
Find out more
CA
Calton & Associates Portfolio holdings
AUM
$683M
1-Year Est. Return
28.95%
This Fund
S&P 500
This Quarter
Est. Return
-2.45%
1 Year Est. Return
+28.95%
3 Year Est. Return
+73.86%
5 Year Est. Return
+79.5%
10 Year Est. Return
–
AUM
$337M
AUM Growth
-$38.2M
(-10%)
Cap. Flow
-$22.4M
Cap. Flow
% of AUM
-6.65%
Top 10 Holdings %
Top 10 Hldgs %
21.59%
Holding
421
New
56
Increased
123
Reduced
161
Closed
72
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VPU
Vanguard Utilities ETF
VPU
|
+$3.29M |
| 2 |
HDV
iShares Core High Dividend ETF
HDV
|
+$2.39M |
| 3 |
Invesco S&P 500 Downside Hedged ETF
PHDG
|
+$1.7M |
| 4 |
Pacer US Cash Cows 100 ETF
COWZ
|
+$1.34M |
| 5 |
Invesco High Yield Equity Dividend Achievers ETF
PEY
|
+$1.13M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$3.5M |
| 2 |
Invesco S&P 500 Pure Growth ETF
RPG
|
+$2.61M |
| 3 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$1.95M |
| 4 |
iShares Core Universal USD Bond ETF
IUSB
|
+$1.83M |
| 5 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$1.75M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 10.34% |
| 2 | Financials | 3.26% |
| 3 | Consumer Discretionary | 3.09% |
| 4 | Healthcare | 2.85% |
| 5 | Industrials | 2.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Exelixis
EXEL
$12.7B
| $207K | 0.06% |
+9,137
| New | +$178K |
|
327
Invesco S&P 500 Low Volatility ETF
SPLV
$7.17B
| $207K | 0.06% |
3,096
-2,194
| -41% | -$143K |
|
328
Repligen
RGEN
$9.3B
| $204K | 0.06% |
1,089
-184
| -14% | -$35K |
|
329
Southern Company
SO
$106B
| $203K | 0.06% |
+2,811
| New | +$190K |
|
330
Vertex Pharmaceuticals
VRTX
$134B
| $202K | 0.06% |
774
-414
| -35% | -$98.3K |
|
331
Fulton Financial
FULT
$4.65B
| $194K | 0.06% |
11,676
-500
| -4% | -$8.94K |
|
332
TriplePoint Venture Growth BDC
TPVG
$214M
| $175K | 0.05% |
+10,031
| New | +$170K |
|
333
Allogene Therapeutics
ALLO
$732M
| $166K | 0.05% |
+18,329
| New | +$191K |
|
|
FOLD
334
DELISTED
Amicus Therapeutics
FOLD
| $165K | 0.05% |
+17,520
| New | +$164K |
|
335
Nuveen AMT-Free Quality Municipal Income Fund
NEA
$3.39B
| $160K | 0.05% |
12,209
-2,133
| -15% | -$29.7K |
|
336
Adaptive Biotechnologies
ADPT
$4.04B
| $157K | 0.05% |
+11,355
| New | +$179K |
|
337
SunCoke Energy
SXC
$786M
| $155K | 0.05% |
+17,481
| New | +$138K |
|
338
NeoGenomics
NEO
$2.12B
| $125K | 0.04% |
+10,355
| New | +$218K |
|
|
MRCC
339
DELISTED
Monroe Capital Corp
MRCC
| $124K | 0.04% |
11,515
-245
| -2% | -$2.67K |
|
|
PMM
340
Franklin Managed Municipal Income Trust
PMM
$273M
| $96K | 0.03% |
13,683
| – | – |
|
341
Omeros
OMER
$984M
| $95K | 0.03% |
15,889
+1,786
| +13% | +$11.1K |
|
342
Kamada
KMDA
$409M
| $94K | 0.03% |
17,158
-1,656
| -9% | -$9.91K |
|
343
CEL-SCI Corp
CVM
$26.6M
| $66K | 0.02% |
567
-136
| -19% | -$22.1K |
|
|
ADAM
344
Adamas Trust
ADAM
$919M
| $62K | 0.02% |
4,250
-246
| -5% | -$3.6K |
|
345
Nektar Therapeutics
NKTR
$2.55B
| $55K | 0.02% |
+690
| New | +$102K |
|
|
ATRS
346
DELISTED
Antares Pharma, Inc.
ATRS
| $51K | 0.02% |
12,500
+1,000
| +9% | +$3.63K |
|
347
Arcadia Biosciences
RKDA
$1.46M
| $18K | 0.01% |
325
| – | – |
|
|
PTN
348
Palatin Technologies
PTN
$13.2M
| $13K | ﹤0.01% |
24
+5
| +26% | +$2.61K |
|
349
TherapeuticsMD
TXMD
$24M
| $3K | ﹤0.01% |
+200
| New | +$3.15K |
|
|
ACB
350
Aurora Cannabis
ACB
$216M
| – | – |
-1,538
| Closed | -$83K |
|
Similar funds
DMC
TWM
NS
CIA
ECM
CCG
MCO
REAM
Calton & Associates's Q1 2022 Portfolio in Review
As of Q1 2022, Calton & Associates held 421 positions worth $337M, down 10% from $375M the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Calton & Associates withdrew a net $22.4M in Q1 2022, closing 72 positions and reducing 161 holdings. Its most notable exit was Invesco S&P 500 Pure Growth ETF, an estimated $2.61M position sold in full.
By sector, the portfolio is most concentrated in Technology at 10% of assets, up from 10% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Calton & Associates opened a new position in iShares Core High Dividend ETF worth $2.46M.
- Calton & Associates's largest Q1 2022 buy was iShares Core High Dividend ETF: 115,050 shares worth $2.46M.
- Calton & Associates added most to Vanguard Utilities ETF in Q1 2022, an estimated $3.29M increase.
- Calton & Associates's biggest Q1 2022 reduction was Invesco QQQ Trust, cutting an estimated $3.5M.
- Calton & Associates fully exited Invesco S&P 500 Pure Growth ETF in Q1 2022, selling an estimated $2.61M.
- Calton & Associates's ten largest holdings make up 22% of its $337M portfolio in Q1 2022.
- Calton & Associates opened 56 new positions and closed 72 in Q1 2022.
- Calton & Associates's portfolio value fell 10% quarter-over-quarter to $337M.
Based on Calton & Associates's 13F filing for Q1 2022, filed 12 Apr 2022.